Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (586)	1/26/2000 12:38:00 AM
From: enervestor	Read Replies (1) \| Respond to of 52153

P&G is already in the pharmaceutical business, but as only a small player. Their CEO just wants them to become a major drug company. It just strikes me as ironic that the stock market is giving internet valuations to genomic companies, but P&G shareholders won't allow their CEO to position the company to be one of the ultimate beneficiaries of the genomic discoveries. Does this mean the market is overvaluing the genomics companies or that P&G shareholders are missing out on 21st century medical technology? The real kicker here is that after calling off the deal, P&G stock has gone down even farther.